ArticleFuture oncology (London, England)2026
Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan.
Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe investigated treatment patterns and healthcare resource utilization (HRU) to clarify unmet medical needs in second and later lines among Japanese patients with advanced non-small cell lung cancer (NSCLC).
methodsThis retrospective study included patients with NSCLC having first-line treatment from a claims database (January 2019-December 2024). Treatment patterns, time to treatment discontinuation (TTD), and HRU were described for patients with/without actionable genomic alteration (AGA) therapy.
resultsOverall, 22,886 patients (with AGA, 7,831; without AGA, 15,055) were included. In patients with AGA, targeted therapy (48.6%), platinum doublet (12.1%), and chemo monotherapy (10.4%) were common second-line treatments, with median TTD 7.5, 4.3, and 3.0 months, respectively. In patients without AGA, chemo monotherapy (45.1%), ICI monotherapy (17.8%), and platinum doublet (13.9%) were the most prescribed second-line treatments with relatively short median TTD (2.7, 3.7, and 3.2 months, respectively). Hospitalization rates were higher in patients with second-line treatment duration <3 versus ≥3 months (incidence/100 person-years, 67-88 vs 35-38).
conclusionTreatment patterns were heterogeneous with short durations that were associated with higher rates of HRU. The study findings highlight the challenge of current treatments, and need for effective treatment options in clinical practice in Japan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.